Targeting the endocannabinoid system: to enhance or reduce? (Q37150745)

18 August 2017

1 reference

title

Targeting the endocannabinoid system: to enhance or reduce? (English)

1 reference

18 August 2017

endocannabinoid system

0 references

Vincenzo Di Marzo

1

0 references

publication date

1 May 2008

1 reference

Nature Reviews Drug Discovery

18 August 2017

1 reference

18 August 2017

7

1 reference

18 August 2017

5

1 reference

18 August 2017

438-455

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2553

18 August 2017

0 references

cites work

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

1 reference

Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression

21 January 2018

1 reference

Cannabinoid pharmacology: the first 66 years

21 January 2018

1 reference

Endocannabinoids and the regulation of their levels in health and disease

21 January 2018

1 reference

The complications of promiscuity: endocannabinoid action and metabolism

21 January 2018

1 reference

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

Endocannabinoid mechanisms of pain modulation

21 January 2018

1 reference

Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain

21 January 2018

1 reference

Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders

21 January 2018

1 reference

CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health

21 January 2018

1 reference

Endocannabinoids and the control of energy balance

21 January 2018

1 reference

The endocannabinoid system and gut-brain signalling.

21 January 2018

1 reference

Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases

21 January 2018

1 reference

The endocannabinoid system as an emerging target of pharmacotherapy

21 January 2018

1 reference

Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol

21 January 2018

1 reference

Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain

21 January 2018

1 reference

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

21 January 2018

1 reference

Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats

21 January 2018

1 reference

Leptin-regulated endocannabinoids are involved in maintaining food intake

21 January 2018

1 reference

Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa

21 January 2018

1 reference

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

21 January 2018

1 reference

Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias

21 January 2018

1 reference

Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

21 January 2018

1 reference

Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

21 January 2018

1 reference

Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease

21 January 2018

1 reference

Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels.

21 January 2018

1 reference

Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade

21 January 2018

1 reference

Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence.

21 January 2018

1 reference

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

21 January 2018

1 reference

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

21 January 2018

1 reference

Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection

21 January 2018

1 reference

The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

21 January 2018

1 reference

Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.

21 January 2018

1 reference

AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

21 January 2018

1 reference

The endogenous cannabinoid system controls extinction of aversive memories

21 January 2018

1 reference

Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes.

21 January 2018

1 reference

Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

An endocannabinoid mechanism for stress-induced analgesia.

21 January 2018

1 reference

Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.

21 January 2018

1 reference

Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.

21 January 2018

1 reference

Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

21 January 2018

1 reference

Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality

21 January 2018

1 reference

In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission

21 January 2018

1 reference

The endocannabinoid system and extinction learning

21 January 2018

1 reference

Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain.

21 January 2018

1 reference

Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats.

21 January 2018

1 reference

Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors

21 January 2018

1 reference

Attenuation of allergic contact dermatitis through the endocannabinoid system

21 January 2018

1 reference

Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors

21 January 2018

1 reference

Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve

21 January 2018

1 reference

A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo

21 January 2018

1 reference

Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats

21 January 2018

1 reference

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

21 January 2018

1 reference

Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury

21 January 2018

1 reference

Peripheral cannabinoid receptor, CB2, regulates bone mass

21 January 2018

1 reference

Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors

21 January 2018

1 reference

Cannabinoids: potential anticancer agents

21 January 2018

1 reference

Endocannabinoid overactivity and intestinal inflammation

21 January 2018

1 reference

Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon

21 January 2018

1 reference

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism

21 January 2018

1 reference

The endogenous cannabinoid system protects against colonic inflammation

21 January 2018

1 reference

Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents

21 January 2018

1 reference

The endocannabinoid system controls key epileptogenic circuits in the hippocampus

21 January 2018

1 reference

Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid typ

21 January 2018

1 reference

Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists

21 January 2018

1 reference

CB2 receptor-mediated migration of immune cells: it can go either way

21 January 2018

1 reference

Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice.

21 January 2018

1 reference

Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis.

21 January 2018

1 reference

Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons

21 January 2018

1 reference

Potentiation of anandamide effects in mesenteric beds isolated from endotoxemic rats

21 January 2018

1 reference

Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors

21 January 2018

1 reference

Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.

21 January 2018

1 reference

Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response

21 January 2018

1 reference

Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk

21 January 2018

1 reference

Modulation of anxiety through blockade of anandamide hydrolysis

21 January 2018

1 reference

Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.

21 January 2018

1 reference

Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets

21 January 2018

1 reference

Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).

21 January 2018

1 reference

The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice

21 January 2018

1 reference

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models

21 January 2018

1 reference

Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors

21 January 2018

1 reference

Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension

21 January 2018

1 reference

Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.

21 January 2018

1 reference

Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat.

21 January 2018

1 reference

Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.

21 January 2018

1 reference

Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.

21 January 2018

1 reference

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats.

21 January 2018

1 reference

The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.

21 January 2018

1 reference

Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference

21 January 2018

1 reference

Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.

21 January 2018

1 reference

Fatty acid amide hydrolase controls mouse intestinal motility in vivo

21 January 2018

1 reference

Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla

21 January 2018

1 reference

Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications

21 January 2018

1 reference

Functional role of high-affinity anandamide transport, as revealed by selective inhibition

21 January 2018

1 reference

Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity

21 January 2018

1 reference

Novel selective and metabolically stable inhibitors of anandamide cellular uptake

21 January 2018

1 reference

Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors

21 January 2018

1 reference

Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.

21 January 2018

1 reference

Identification of a high-affinity binding site involved in the transport of endocannabinoids

21 January 2018

1 reference

Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation

21 January 2018

1 reference

AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain

21 January 2018

1 reference

Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide].

21 January 2018

1 reference

Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear

21 January 2018

1 reference

Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test

21 January 2018

1 reference

Anxiolytic-like properties of the anandamide transport inhibitor AM404.

21 January 2018

1 reference

5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats

21 January 2018

1 reference

CB1 cannabinoid receptors and on-demand defense against excitotoxicity

21 January 2018

1 reference

Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.

21 January 2018

1 reference

Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation

21 January 2018

1 reference

Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function

21 January 2018

1 reference

Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours.

21 January 2018

1 reference

New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis

21 January 2018

1 reference

In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake

21 January 2018

1 reference

UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.

21 January 2018

1 reference

Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis.

21 January 2018

1 reference

Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits.

21 January 2018

1 reference

Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew

21 January 2018

1 reference

Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats

21 January 2018

1 reference

Discovering potent and selective reversible inhibitors of enzymes in complex proteomes

21 January 2018

1 reference

Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity

21 January 2018

1 reference

The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases

21 January 2018

1 reference

Receptor-independent effects of endocannabinoids on ion channels

21 January 2018

1 reference

Biochemistry and pharmacology of endovanilloids

21 January 2018

1 reference

Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

21 January 2018

1 reference

Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597).

21 January 2018

1 reference

The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors

21 January 2018

1 reference

The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation

21 January 2018

1 reference

Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase

21 January 2018

1 reference

Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors

21 January 2018

1 reference

Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system

21 January 2018

1 reference

The anandamide transport inhibitor AM404 activates vanilloid receptors.

21 January 2018

1 reference

Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors

21 January 2018

1 reference

Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport.

21 January 2018

1 reference

Further evidence for the existence of a specific process for the membrane transport of anandamide

21 January 2018

1 reference

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

21 January 2018

1 reference

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

21 January 2018

1 reference

Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats

21 January 2018

1 reference

CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats

21 January 2018

1 reference

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents

21 January 2018

1 reference

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization

21 January 2018

1 reference

Endocannabinoid signalling in the blood of patients with schizophrenia

21 January 2018

1 reference

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms

21 January 2018

1 reference

Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

21 January 2018

1 reference

Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats

21 January 2018

1 reference

CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat

21 January 2018

1 reference

A cannabinoid mechanism in relapse to cocaine seeking.

21 January 2018

1 reference

Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

21 January 2018

1 reference

Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice

21 January 2018

1 reference

Rimonabant: more than an anti-obesity drug?

21 January 2018

1 reference

Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

21 January 2018

1 reference

Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats

21 January 2018

1 reference

Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats

21 January 2018

1 reference

Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice.

21 January 2018

1 reference

Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear.

21 January 2018

1 reference

Development of the first potent and specific inhibitors of endocannabinoid biosynthesis

21 January 2018

1 reference

Cannabinoid-based drugs as anti-inflammatory therapeutics

21 January 2018

1 reference

Multiple pathways involved in the biosynthesis of anandamide

21 January 2018

1 reference

A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol

21 January 2018

1 reference

Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids

21 January 2018

1 reference

Prostamides (prostaglandin-ethanolamides) and their pharmacology

21 January 2018

1 reference

The orphan receptor GPR55 is a novel cannabinoid receptor

21 January 2018

1 reference

Identification of GPR55 as a lysophosphatidylinositol receptor

21 January 2018

1 reference

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

21 January 2018

1 reference

Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes

21 January 2018

1 reference

Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity

21 January 2018

1 reference

Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin

21 January 2018

1 reference

Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms

21 January 2018

1 reference

Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro

21 January 2018

1 reference

Allergic contact dermatitis and the endocannabinoid system: from mechanisms to skin care

21 January 2018

1 reference

Cannabinoids and cardiovascular disease: the outlook for clinical treatments

31 March 2020

1 reference

Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.

31 March 2020

1 reference

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

31 March 2020

1 reference

Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains

31 March 2020

1 reference

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

31 March 2020

1 reference

Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex

31 March 2020

1 reference

Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice.

31 March 2020

1 reference

Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice

31 March 2020

1 reference

Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice

31 March 2020

1 reference

Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain

31 March 2020

1 reference

Cannabinoids hurt, heal in cirrhosis

31 March 2020

1 reference

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

31 March 2020

1 reference

Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease

31 March 2020

1 reference

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

31 March 2020

1 reference

Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation

31 March 2020

1 reference

The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level

31 March 2020

1 reference

Involvement of the Endocannabinoid System in Retinal Damage after High Intraocular Pressure–Induced Ischemia in Rats

31 March 2020

1 reference

A new strategy to block tumor growth by inhibiting endocannabinoid inactivation

31 March 2020

1 reference

Endocannabinoids control spasticity in a multiple sclerosis model

31 March 2020

1 reference

A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats

31 March 2020

1 reference

AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide

31 March 2020

1 reference

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

31 March 2020

1 reference

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

31 March 2020

1 reference

The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms

31 March 2020

1 reference

Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in

31 March 2020

1 reference

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys

31 March 2020

1 reference

Novel inhibitors of fatty acid amide hydrolase

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2553

1 reference

18 August 2017

1 reference

PubMed ID

18446159